23,20 €
Deine Einschätzung
Agios Pharmaceuticals Inc. Aktie
Was spricht für und gegen Agios Pharmaceuticals Inc. in den nächsten Jahren?
Pro
Kontra
Rendite von Agios Pharmaceuticals Inc. im Vergleich
| Wertpapier | Ver.(%) | 1W | 1M | 1J | YTD | 3J | 5J |
|---|---|---|---|---|---|---|---|
| Agios Pharmaceuticals Inc. | -2,52 % | -4,13 % | 0,00 % | -27,95 % | 0,00 % | -18,31 % | -40,13 % |
| Ironwood Pharmaceuticals | 1,00 % | -7,31 % | 52,63 % | 15,34 % | 52,63 % | -60,88 % | -52,79 % |
| Novocure Ltd | 1,84 % | -13,32 % | -7,59 % | -57,28 % | -7,59 % | -87,48 % | -92,10 % |
| Iovance Biotherapeutics Inc. | -0,46 % | -3,68 % | -9,46 % | -64,04 % | -9,46 % | -70,72 % | -94,05 % |
Kommentare
News
Here's Why Shares in Agios Pharmaceuticals Popped Today
Shares in Agios Pharmaceuticals (NASDAQ: AGIO) soared by more than 18% as of 11 a.m. today. The move follows the company's receipt of approval from the Food and Drug Administration (FDA) for AQVESME
Why Shares in Agios Pharmaceuticals Got Crushed Today
Shares in Agios Pharmaceuticals (NASDAQ: AGIO) crashed by 50% by noontime today. The move comes as the market digests a mixed set of topline results from its Phase 3 trial (RISE UP) of its sickle
Agios (AGIO) Q2 Revenue Jumps 45%
Agios Pharmaceuticals (NASDAQ:AGIO), a biotechnology company focused on therapies for rare blood disorders, released its second quarter 2025 earnings on July 31, 2025. The headline was a notable



